Array Biopharma

Ambrosia lands $16m to ‘improve on existing GLP-1 drugs’
Longevity Technology
Wed, 08/21/24 - 11:26 am
Ambrosia Biosciences
funding
GLP-1 agonists
obesity
Pfizer
Array Biopharma
Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’
Pharmaforum
Mon, 07/8/19 - 09:48 am
Braftovi
Array Biopharma
Pierre Fabre
Eli Lilly
Mektovi
Erbitux
colorectal cancer
clinical trials
Two years into dance, BEACON data clinched Pfizer-Array deal
BioCentury
Mon, 07/1/19 - 11:55 am
Pfizer
Array Biopharma
Braftovi
Mektovi
These 3 Biotech Stocks Skyrocketed Last Week
Motley Fool
Mon, 06/24/19 - 09:42 am
Array Biopharma
Pfizer
M&A
G1 Therapeutics
trilaciclib
Cel-Sci
Array-size deals don’t come around too often
EP Vantage
Tue, 06/18/19 - 11:34 pm
M&A
Pfizer
Array Biopharma
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Motley Fool
Tue, 06/18/19 - 11:54 am
Pfizer
Array Biopharma
M&A
Amgen
Gilead Sciences
Biogen
Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon
Motley Fool
Mon, 06/17/19 - 11:28 pm
Pfizer
Array Biopharma
M&A
Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist
TheStreet.com
Mon, 06/17/19 - 10:20 am
Pfizer
Array Biopharma
M&A
cancer
colorectal cancer
3 Cancer Stocks Given a Lift by Amgen
Motley Fool
Tue, 06/4/19 - 11:07 am
Amgen
KRAS
AMG 510
Mirati Therapeutics
Array Biopharma
Gilead Sciences
ASCO 2019
Array gets a win in colorectal cancer
Biopharma Dive
Tue, 05/21/19 - 11:01 pm
Array Biopharma
Braftovi
Mektovi
colorectal cancer
Here's Why Array BioPharma Jumped 31% in January
Motley Fool
Mon, 02/4/19 - 09:53 am
Array Biopharma
Eli Lilly
Braftovi
Mektovi
Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?
Motley Fool
Wed, 01/9/19 - 09:43 am
Eli Lilly
Loxo Oncology
Array Biopharma
M&A
Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
CP Wire
Fri, 08/3/18 - 09:25 am
AstraZeneca
Merck
selumetinib
Array Biopharma
orphan drugs
NF1
neurofibromatosis
Failed as a Cancer Treatment - Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1
Fri, 08/3/18 - 09:23 am
AstraZeneca
Merck
selumetinib
Array Biopharma
Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi
Endpoints
Wed, 06/27/18 - 09:44 pm
Array Biopharma
binimetinib
Mektovi
Braftovi
melanoma
Encorafenib and Binimetinib Combination Results Show Improved Survival in BRAF-Mutant Advanced Melanoma Patient
CP Wire
Mon, 06/4/18 - 09:16 am
Array Biopharma
encorafenib
binimetinib
advanced melanoma
ASCO 2018
3 Biotechs With Huge FDA Decisions in June
Motley Fool
Thu, 05/31/18 - 10:00 pm
biotech
Array Biopharma
encorafenib
binimetinib
GW Pharma
Epidiolex
Incyte
olumiant
AstraZeneca owes $192M in royalties from massive Merck deal, selumetinib licensor Array argues
Fierce Pharma
Wed, 03/21/18 - 09:19 am
AstraZeneca
Merck
selumetinib
Array Biopharma
Array melanoma drugs show significant survival versus Roche drug in study
Reuters
Wed, 02/7/18 - 09:58 am
Array Biopharma
melanoma
Roche
encorafenib
binimetinib
Array Biopharma ties up with Pfizer on cancer-fighting combos
Fierce Biotech
Wed, 12/20/17 - 09:51 am
Array Biopharma
Pfizer
clinical trials
binimetinib
talazoparib
Merck KGaA
Bavencio
cancer

Pages